<?xml version="1.0" encoding="UTF-8"?><ns2:project xmlns:ns1="http://gtr.rcuk.ac.uk/gtr/api" xmlns:ns2="http://gtr.rcuk.ac.uk/gtr/api/project" xmlns:ns3="http://gtr.rcuk.ac.uk/gtr/api/fund" xmlns:ns4="http://gtr.rcuk.ac.uk/gtr/api/person" xmlns:ns5="http://gtr.rcuk.ac.uk/gtr/api/project/outcome" xmlns:ns6="http://gtr.rcuk.ac.uk/gtr/api/organisation" ns1:created="2026-08-26T13:36:10Z" ns1:href="http://gtr.ukri.org/gtr/api/projects/89FE482A-2187-454E-8E39-7480338E6C36" ns1:id="89FE482A-2187-454E-8E39-7480338E6C36"><ns1:links><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/persons/E9EC26A1-B069-4234-8C53-F92814AFA8E7" ns1:rel="PM_PER"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/76FEB2C2-3534-4B26-ADC7-CF2073028C83" ns1:rel="LEAD_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/BFE41CB6-4B8A-4082-B96B-3DFEFE793924" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/76FEB2C2-3534-4B26-ADC7-CF2073028C83" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:end="2020-11-30T00:00:00Z" ns1:href="http://gtr.ukri.org/gtr/api/funds/882BB58A-BB3C-492F-A022-3F749EAB1135" ns1:rel="FUND" ns1:start="2017-06-30T23:00:00Z"/></ns1:links><ns2:identifiers><ns2:identifier ns2:type="RCUK">103357</ns2:identifier></ns2:identifiers><ns2:title>VIVODOTS™ nano-devices for detection, resection and management of pancreatic cancers</ns2:title><ns2:status>Closed</ns2:status><ns2:grantCategory>Collaborative R&amp;D</ns2:grantCategory><ns2:leadFunder>Innovate UK</ns2:leadFunder><ns2:abstractText>A cancer imaging and therapeutic nano-device will be developed to enable better detection and treatment of lethal types of tumours, particularly pancreatic tumours. The design will be based on the use of biocompatible and fluorescent quantum dot nanoparticles (QDs) equipped with specific cancer targeting molecules. The proposed nano-device will enable more effective pre-, intra-, and post-operative management of pancreatic cancers, resulting in better surgical treatment, higher cure rates, and better quality of life for survivors. Later development should lead to the extrapolation of the same concept to other types of deadly malignancies.</ns2:abstractText></ns2:project>